Ionis Pharmaceuticals, Inc. (FRA:ISI)

Germany · Delayed Price · Currency is EUR

69.82

-0.12 (-0.17%)

At close: Dec 4, 2025

106.38% (1Y)

Market Cap	11.37B
Revenue (ttm)	824.14M
Net Income (ttm)	-218.48M
Shares Out	n/a
EPS (ttm)	-1.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	44
Open	69.82
Previous Close	69.94
Day's Range	69.82 - 69.82
52-Week Range	22.73 - 71.62
Beta	n/a
RSI	66.48
Earnings Date	Feb 18, 2026

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSE... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 1989

Employees 1,069

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol ISI

Full Company Profile

Financial Performance

In 2024, Ionis Pharmaceuticals's revenue was $705.14 million, a decrease of -10.48% compared to the previous year's $787.65 million. Losses were -$453.90 million, 23.9% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.